While in agreement to your comments - and those of procrastinator and lakota6 - I shall be on record for the following:
- There will not be a CR on the back of the results for BTX1308's phase 1. - As psoriasis and Atopic Dermatatis are both T-cell mediated inflammatory diseases of the skin, successful data from that trial bodes well for BTX1204's phase 2. - BTX1503's trial is currently at "recruitment peak" so it's still a bit early for sp movements on 'visual' basis. -If BTX1503's trial data is good, that's a game changer and any future CR will be done at a premium.
Patience is a tricky beast to ride.
BOT Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)